The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 20, 2022

Filed:

Nov. 21, 2018
Applicant:

Los Angeles Biomedical Research Institute AT Harbor-ucla Medical Center, Torrance, CA (US);

Inventor:

Guochuan Emil Tsai, Pasadena, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/47 (2006.01); A61K 31/11 (2006.01); A61K 31/12 (2006.01); A61K 31/13 (2006.01); A61K 31/16 (2006.01); A61K 31/19 (2006.01); A61K 31/22 (2006.01); A61K 31/235 (2006.01); A61K 31/245 (2006.01); A61K 31/35 (2006.01); A61K 31/382 (2006.01); A61K 31/5513 (2006.01); A61K 33/00 (2006.01); A61K 36/16 (2006.01); A61K 45/06 (2006.01); A61K 31/196 (2006.01); A61P 25/00 (2006.01); A61K 31/192 (2006.01); A61K 31/167 (2006.01); A61K 31/27 (2006.01); A61K 31/438 (2006.01); A61K 31/445 (2006.01);
U.S. Cl.
CPC ...
A61K 31/47 (2013.01); A61K 31/11 (2013.01); A61K 31/12 (2013.01); A61K 31/13 (2013.01); A61K 31/16 (2013.01); A61K 31/167 (2013.01); A61K 31/19 (2013.01); A61K 31/192 (2013.01); A61K 31/196 (2013.01); A61K 31/22 (2013.01); A61K 31/235 (2013.01); A61K 31/245 (2013.01); A61K 31/27 (2013.01); A61K 31/35 (2013.01); A61K 31/382 (2013.01); A61K 31/438 (2013.01); A61K 31/445 (2013.01); A61K 31/5513 (2013.01); A61K 33/00 (2013.01); A61K 36/16 (2013.01); A61K 45/06 (2013.01); A61P 25/00 (2018.01);
Abstract

Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.


Find Patent Forward Citations

Loading…